CS
AMED

Candriam SCA’s Amedisys AMED Stock Holding History

Candriam SCA’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-70,000
Closed -$6.4M – 660
2023
Q2 		$6.4M Buy
70,000
+44,440
+174% +$3.65M 0.05% 302
2023
Q1 		$1.73M Buy
25,560
+1,250
+5% +$108K 0.01% 601
2022
Q4 		$2.03M Buy
24,310
+2,028
+9% +$183K 0.01% 576
2022
Q3 		$2.16M Buy
22,282
+8,282
+59% +$988K 0.02% 567
2022
Q2 		$1.47M Hold
14,000
– – 0.01% 563
2022
Q1 		$2.41M Hold
14,000
– – 0.02% 504
2021
Q4 		$5.95M Buy
+14,000
New +$2.25M 0.04% 326

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Candriam SCA's AMED Position: Q3 2023 in Review

Candriam SCA sold out of Amedisys (AMED) in Q3 2023, closing a stake of 70,000 shares — an estimated $6.4M sold.

Candriam SCA first reported a position in AMED in Q4 2021 and held it in 7 quarters. The position peaked at $6.4M in Q2 2023. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2023.

  • Candriam SCA reported no remaining Amedisys position as of Q3 2023 after selling out during the quarter.
  • Candriam SCA sold 70,000 Amedisys shares in Q3 2023, an estimated $6.4M.
  • Candriam SCA first reported a position in Amedisys in Q4 2021 and held it in 7 quarters.
  • Candriam SCA's Amedisys position peaked at $6.4M in Q2 2023.
  • 286 funds tracked by Wall St. Rank held Amedisys as of Q3 2023.

Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.